Случай развития вторичного миелоидного лейкоза у пациента с нейробластомой

Статья в Elpub

Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2020; 19: 105-113

Случай развития вторичного миелоидного лейкоза у пациента с нейробластомой

Уталиева Д. Т., Калинина И. И., Качанов Д. Ю., Евсеев Д. А., Щербаков А. П., Дубровина М. Э., Моисеенко Р. А., Ликарь Ю. Н., Шаманская Т. В.

https://doi.org/10.24287/1726-1708-2020-19-3-105-113

Аннотация

Современные успехи детской онкологии улучшили показатели выживаемости пациентов с нейробластомой (НБ) группы промежуточного и высокого риска. В то же время интенсивная мультимодальная терапия приводит к увеличению частоты встречаемости вторичных злокачественных новообразований у выживших пациентов. В настоящее время известно, что алкилирующие агенты, ингибиторы топоизомеразы II и препараты платины могут приводить к развитию вторичного острого миелоидного лейкоза (ОМЛ). В данной статье представлены литературный обзор и описание клинического случая развития вторичного ОМЛ через 57 мес от установления первичного диагноза у пациента с НБ группы промежуточного риска, получавшего интенсивную химиотерапию в 1-й линии и в рецидиве заболевания. Дебют вторичного ОМЛ потребовал выполнения ряда диагностических исследований для исключения рецидива НБ. Родители дали согласие на использование информации, в том числе фотографий ребенка, в научных исследованиях и публикациях.

Список литературы

1. Morgan J.E., Walker R., Harden M., Phillips R.S. A systematic review of evidence for and against routine surveillance imaging after completing treatment for childhood extracranial solid tumors. Сancer Med 2020; 9 (14): 4949–61. DOI: 10.1002/cam4.3110

2. Gibson M.T., Mostoufi-Moab S., Stratton K.L., Leisenring W.M., Barnea D., Chow E.J., et al. Temporal patterns in the risk of chronic health conditions in survivors of childhood cancer diagnosed 1970–99: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol 2018; 19 (12): 1590– 601. DOI: 10.1016/S1470-2045(18)30537-0

3. American Academy of Pediatrics Section on Hematology/Oncology Childrens Oncology Group. Long-term Follow-up Care for Pediatric Cancer Survivors. Pediatrics 2009; 123 (3): 906–15. DOI: 10.1542/peds.2008-3688

4. Elzembely M.M., Dahlberg A.E., Pinto N., Leger K., Chow E., Park R., et al. Late effects in high-risk neuroblastoma survivors treated with high-dose chemotherapy and stem cell rescue. Pediatr Blood Cancer 2019; 66 (1): e27421. DOI: 10.1002/pbc.27421

5. Friedman D.N., Henderson T.O. Late Effects and Survivorship Issues in Patients with Neuroblastoma. Children (Basel) 2018; 5 (8): 107. DOI: 10.3390/children5080107

6. Laverdie`re C., Cheung N.V., Kushner B.H., Kramer K., Modak S., LaQuaglia M.P., et al. Long-term complications in survivors of advanced stage neuroblastoma. Pediatr Blood Cancer 2005; 45 (3): 324–32. DOI: 10.1002/pbc.20331

7. Laverdière C., Liu Q., Yasui Y., Nathan P.C., Gurney J., Stovall M., et al. Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2009; 101 (16): 1131–40. DOI: 10.1093/jnci/djp230

8. Berthold F., Hömberg M., Proleskovskaya I., Mazanek P., Belogurova M., Ernst A., et al. Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma. Pediatr Hematol Oncol 2017; 34 (5): 308–19. DOI: 10.1080/08880018.2017.1373314

9. Goodman M.S., Gurney J.G., Smith M.A., Olshan A.F. Sympathetic nervous system tumors. In Ries L.A.G, Smith M.A., Gurney J.G., et al. (eds). Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975–1995, National Cancer Institute, SEER Program. NIH Pub. No. 99–4649. Bethesda, MD; 1999. P. 65–72.

10. D’Angio G.J., Evans A.E., Koop C.E. Special pattern of widespread neuroblastoma with a favourable prognosis. Lancet 1971; 1 (7708): 1046–9. DOI: 10.1016/s0140-6736(71)91606-0

11. Seeger R.C., Reynolds C.P. Neuroblastoma. In: Bone Marrow Transplantation. Ed. by Forman S.J., Blume K.G., Thomas E.D. Cambridg, England: Blacwell; 1994. Pp. 814–826.

12. Thorsten S., Barbara H., Schulte J.H., Deubzer H., Hundsdoerfer P., von Schweinitz D., et al. 2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors. Klin Padiatr 2017; 229 (3): 147–67. DOI: 10.1055/s-0043-103086

13. Moroz V., Machin D., Faldum A., Hero B., Iehara T., Mosseri V., et al. Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group Project. Eur J Cancer 2011; 47 (4): 561–71. DOI: 10.1016/j.ejca.2010.10.022

14. Applebaum M.A., Henderson T.O., Lee S.M., Pinto N., Volchenboum S.L., Cohn S.L. Second malignancies in patients with neuroblastoma: the effects of risk-based therapy pediatr. Blood Cancer 2015; 62 (1): 128–33. DOI: 10.1002/pbc.25249

15. Applebaum M.A., Vaksman Z., Lee S.M., Hungate E.A., Henderson T.O., London W.B., et al. Neuroblastoma Survivors are at Increased Risk for Second Malignancies: A Report from the International Neuroblastoma Risk Group Project. Eur J Cancer 2017; 72: 177–85. DOI: 10.1016/j.ejca.2016.11.022

16. Kreissman S.G., Seeger R.C., Matthay K.K., London W.B., Sposto R., Grupp S.A., et al. Purged versus nonpurged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol 2013; 14 (10): 999–1008. DOI: 10.1016/S1470-2045(13)70309-7

17. Kushner B.H., Kramer K., Modak S., Qin L.X., Yataghena K., Jhanwar S.C., et al. Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastoma. Pediatr Blood Cancer 2009; 53 (1): 17–22. DOI: 10.1002/pbc.21931

18. Martin A., Schneiderman J., Helenowski I.B., Morgan E., Dilley K., Danner-Koptik K., et al. Secondary Malignant Neoplasms After High-Dose Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma. Pediatr Blood Cancer 2014; 61 (8): 1350–6. DOI: 10.1002/pbc.25033

19. Rubino C., Adjadj E., Guérin S., Guibout C., Shamsaldin A., Dondon M., et al. Longterm risk of second malignant neoplasms after neuroblastoma in childhood: role of treatment. Int J Cancer 2003; 107 (5): 791–6. DOI: 10.1002/ijc.11455

20. Garaventa A., Gambini C., Villavecchia G., Cataldo A.D., Bertolazzi L., Pizzitola M.R., et al. Second Malignancies in Children with Neuroblastoma after Combined Treatment with 131I-metaiodobenzylguanidine. Cancer 2003; 97 (5): 1332–8. DOI: 10.1002/cncr.11167

21. Arber D.A., Orazi A., Hasserjian R., Thiele J., Borowitz M. J., Beau M., et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127 (20): 2391–405. DOI: 10.1182/blood-2016-03-643544

22. Smith M.A., Rubinstein L., Ungerleider R.S. Therapy-Related Acute Myeloid Leukemia Following Treatment with Epipodophyllotoxins: Estimating the Risks. Med Pediatr Oncol 1994; 23 (2): 86–98. DOI: 10.1002/mpo.2950230205

23. Godley L.A, Larson R.A. Therapy-related myeloid leukemia. Semin Oncol 2008; 35 (4): 418–29. DOI: 10.1053/j.seminoncol.2008.04.012

24. Deley L., Leblanc T., Shamsaldin A., Raquin M.A., Lacour B., Sommelet D., et al. Risk of Secondary Leukemia After a Solid Tumor in Childhood According to the Dose of Epipodophyllotoxins and Anthracyclines: A Case-Control Study by the Société Française d'Oncologie Pédiatrique. J Clin Oncol 2003; 21 (6): 1074– 81. DOI: 10.1200/JCO.2003.04.100

25. Kern W., Haferlach T., Schnittger S., Hiddemann W., Schoch C. Prognosis in Therapy-Related Acute Myeloid Leukemia and Impact of Karyotype. J Clin Oncol 2004; 22 (12): 2510–1. DOI: 10.1200/JCO.2004.99.301

26. Cho H.W., Choi Y.B., Yi E.S., Lee J.W., Sung K.W., Koo H.H., et al. Therapy-related myeloid neoplasms in children and adolescents. Blood Res 2016; 51 (4): 242–8. DOI: 10.5045/br.2016.51.4.242

27. Santos-Machado T.M., Zerbini M.C., Cristofani L.M., Azevedo P.M., Almeida M.T., Maluf P.T. Jr, Odone-Filho V. Simultaneous occurrence of advanced neuroblastoma and acute myeloid leukemia. Pediatr Hematol Oncol 2001; 18 (2): 129–35. DOI: 10.1080/088800101300002964

28. Vafaie M., Jaseb K., Fekri K., Haghi S. Simultaneous occurrence of advanced neuroblastoma and acute lymphoblastic leukemia: a case report. Middle East J Cancer 2011; 2 (1): 33–6.

29. Sylvia M.T., Rani J., Basu D., Kar R., Dubashi B. Concurrent Presentation of Therapy Related Acute Myeloid Leukemia in a Case of Neuroblastoma. Indian J Hematol Blood Transfus 2016; 32 (Suppl 1): 11–4. DOI: 10.1007/s12288-015-0518-1

30. Qin N., Wang Z., Liu Q., Song N., Wilson C.L., Ehrhardt M.J., et al. Pathogenic Germline Mutations in DNA Repair Genes in Combination with Cancer Treatment Exposures and Risk of Subsequent Neoplasms Among Long-Term Survivors of Childhood Cancer. J Clin Oncol 2020; JCO1902760 DOI: 10.1200/JCO.19.02760

Pediatric Hematology/Oncology and Immunopathology. 2020; 19: 105-113

Therapy-related acute myeloid leukemia in a patient with neuroblastoma: case report

Utalieva D. T., Kalinina I. I., Kachanov D. Yu., Evseev D. A., Shcherbakov A. P., Dubrowina M. Ye., Moiseenko R. A., Likar Yu. N., Shamanskaya T. V.

https://doi.org/10.24287/1726-1708-2020-19-3-105-113

Abstract

Modern, risk-adapted treatment approaches for intermediate and high-risk neuroblastoma (NB) have led to an increasing numbers of survivors. However, intensive multimodal treatment strategy is associated with a significantly increased risk of secondary malignancies. It is currently known that alkylating agents, topoisomerase II inhibitors, and platinum compounds induce treatment-related leukemia. This article presents a literature review and description of a clinical case of secondary acute myeloid leukemia (s-AML) developed 57 months after the initial diagnosis in a patient with intermediate-risk NB who received intensive first-line and post-relapse chemotherapy. The debut of s-AML required a differential diagnosis to rule out a relapse of NB. Parents gave their consent to use information about the child, including fotos, in the article.

References

1. Morgan J.E., Walker R., Harden M., Phillips R.S. A systematic review of evidence for and against routine surveillance imaging after completing treatment for childhood extracranial solid tumors. Sancer Med 2020; 9 (14): 4949–61. DOI: 10.1002/cam4.3110

5. Friedman D.N., Henderson T.O. Late Effects and Survivorship Issues in Patients with Neuroblastoma. Children (Basel) 2018; 5 (8): 107. DOI: 10.3390/children5080107

10. D’Angio G.J., Evans A.E., Koop C.E. Special pattern of widespread neuroblastoma with a favourable prognosis. Lancet 1971; 1 (7708): 1046–9. DOI: 10.1016/s0140-6736(71)91606-0

11. Seeger R.C., Reynolds C.P. Neuroblastoma. In: Bone Marrow Transplantation. Ed. by Forman S.J., Blume K.G., Thomas E.D. Cambridg, England: Blacwell; 1994. Pp. 814–826.

23. Godley L.A, Larson R.A. Therapy-related myeloid leukemia. Semin Oncol 2008; 35 (4): 418–29. DOI: 10.1053/j.seminoncol.2008.04.012

26. Cho H.W., Choi Y.B., Yi E.S., Lee J.W., Sung K.W., Koo H.H., et al. Therapy-related myeloid neoplasms in children and adolescents. Blood Res 2016; 51 (4): 242–8. DOI: 10.5045/br.2016.51.4.242

28. Vafaie M., Jaseb K., Fekri K., Haghi S. Simultaneous occurrence of advanced neuroblastoma and acute lymphoblastic leukemia: a case report. Middle East J Cancer 2011; 2 (1): 33–6.